title: Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
abstract: OBJECTIVE
  To assess the cost-effectiveness ratio of rifampin for 4 months and isoniazid for 6 months in contacts with latent tuberculosis infection.
  
  
  METHODS
  The cost was the sum of the cost of treatment with isoniazid for 6 months or with rifampin for 4 months of all contacts plus the cost of treatment of cases of tuberculosis not avoided. The effectiveness was the number of cases of tuberculosis avoided with isoniazid for 6 months or with rifampin for 4 months. When the cost with one schedule was found to be cheaper than the other and a greater number of tuberculosis cases were avoided, this schedule was considered dominant. The efficacy adopted was 90% for rifampin for 4 months and 69% for isoniazid for 6 months. A sensitivity analysis was made for efficacies of rifampin for 4 months of 80%, 69%, 60% and 50%.
  
  
  RESULTS
  Of the 1002 patients studied, 863 were treated with isoniazid for 6 months and 139 with rifampin for 4 months The cost-effectiveness ratio with isoniazid for 6 month was € 19759.48/avoided case of tuberculosis and € 8736.86/avoided case of tuberculosis with rifampin for 4 months. Rifampin for 4 months was dominant. In the sensitivity analysis, rifampin for 4 months was dominant for efficacies from 60%.
  
  
  CONCLUSIONS
  Rifampin for 4 months was more cost-effective than isoniazid for 6 months.
authors.affiliation: Catalan Health Institute (ICS), Department of Health, Generalitat of Catalonia, Spain.
authors.forename: José Ma
authors.initials: JM
authors.lastname: Pina
authors.forename: Laura
authors.initials: L
authors.lastname: Clotet
authors.forename: Anna
authors.initials: A
authors.lastname: Ferrer
authors.forename: María Rosa
authors.initials: MR
authors.lastname: Sala
authors.forename: Patricio
authors.initials: P
authors.lastname: Garrido
authors.forename: Lluis
authors.initials: L
authors.lastname: Salleras
authors.forename: Angela
authors.initials: A
authors.lastname: Domínguez
mesh_terms: D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data*; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D055985:Latent Tuberculosis / Q000188:drug therapy* / Q000191:economics; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013030:Spain; D016896:Treatment Outcome; D014374:Tuberculin Test; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin